Gleevec For What? Imatinib NDA For PAH Will Face Safety Questions At Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis said there was a higher rate of unspecified serious adverse events in the active arm of the pivotal trial for pulmonary arterial hypertension.